Tag: Alliqua BioMedical

YARDLEY, Pa. - Alliqua BioMedical has sold its TheraBond 3D Antimicrobial Barrier Systems product line to Argentum Medical, a manufacturer of metallic silver-based, antimicrobial wound dressings, for approximately $.38 million, it announced Sept. 5. Alliqua will use sale proceeds for working capital purposes and to reduce its outstanding debt balance. Argentum is a portfolio company of Shore Capital Partners, a private equity firm.

WASHINGTON - Results are in for the AAHomecare HME Audit Key survey for the first quarter of 2016.Sixty-nine percent of completed MAC prepayment audits nationwide were paid upon review, according to the survey, which included additional documentation requests from Oct. 1, 2015, through March 31, 2016.Other results from the survey:. the average rate of audits denied increased 5% between the fourth quarter of 2015 and the first quarter of 2016, with the average percent of audits denied by net revenue...

YARDLEY, Pa. - Alliqua BioMedical, a provider of advanced wound care products, reported revenues of $4.6 million for the first quarter of 2016, an increase of 120% over the same period a year ago. Organic total growth was approximately 4%. Product revenue was $4.1 million for the quarter, a 177% increase over the same period in 2015. “We remain extremely encouraged by the compelling commercial opportunity for our portfolio of advanced wound care technologies and expect that our continued execution...

LANGHORNE, Pa. - Alliqua Medical has announced a public offering of common stock. The provider of advanced wound care products has announced pricing of an underwritten public offering of 6.6 million of its common stock at a price to the public of $4.55 per share. It expects to close the offering on May 4. Alliqua will use net proceeds from the offering to fund the expansion of its marketed products, explore additional products platforms and increase working capital, according to a press release.

LANGHORNE, Pa. - Alliqua BioMedical, a maker of wound care products, has agreed to acquire Eden Prairie-based Celleration for $30.4 million in stock and cash, according to an article in the Philadelphia Business Journal. Celleration is the manufacturer of MIST Therapy, an ultrasound system for treating acute and chronic wounds. Celleration had revenues of about $8.7 million in 2014. The deal will nearly double the size of Alliqua's sales force, said CEO David Johnson in the article.